A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Voorhees PM, et al.
British Journal of Haematology, 161(3), 357-366 (2013)
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara K and Hirano T
Cytokine & Growth Factor Reviews, 13(4-5), 357-368 (2002)
Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines.
Ehrin J Armstrong et al.
Circulation, 113(6), e72-e75 (2006-02-16)
L M Biasucci et al.
Circulation, 94(5), 874-877 (1996-09-01)
Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that...
Mehmet Kocoglu et al.
Pharmaceuticals (Basel, Switzerland), 9(1) (2016-01-20)
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic...